Sarcopenic obesity in comorbid patients
- Authors: Zuikova A.A.1, Shevcova V.I.1, Shevcov A.N.1, Kurguzova A.S.1
-
Affiliations:
- Voronezh State Medical University
- Issue: Vol 13, No 4 (2022)
- Pages: 60-67
- Section: Reviews
- URL: https://journals.rcsi.science/clinpractice/article/view/144170
- DOI: https://doi.org/10.17816/clinpract112438
- ID: 144170
Cite item
Full Text
Abstract
Sarcopenia is a multifactorial syndrome with an insufficiently studied pathogenesis, manifested by a generalized loss of muscle mass and skeletal muscle strength. Despite the fact that sarcopenia is a risk factor for mortality and disability, especially in the elderly, this pathology is rarely diagnosed. The lack of the uniform criteria for the diagnosis and comorbidity of the elderly patients create difficulties in the differential diagnosis of this condition. Sarcopenia is most often combined with endocrine pathologies, such as obesity and diabetes mellitus. An accelerated decrease in the muscle mass leads to a decrease in insulin sensitivity, resulting in insulin resistance, which, in turn, leads to the excessive accumulation of adipose tissue — sarcopenic obesity. The results of the studies indicate a higher risk of metabolic syndrome, type 2 diabetes mellitus and atherosclerosis among individuals with sarcopenic obesity, as opposed to those with simple obesity or sarcopenia. A vicious circle consisting of age-related changes in the skeletal muscles, obesity and impaired glucose regulation leads to a more severe course of diseases and a negative impact on a person's life expectancy. Due to the fact that there are presently no clear criteria for the diagnosis of sarcopenic obesity, there are no unambiguous data on its prevalence. A search for the modern methods of research, prevention and treatment of this condition is required.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Anna A. Zuikova
Voronezh State Medical University
Email: zuikova-terapia23@mail.ru
ORCID iD: 0000-0003-2392-3134
SPIN-code: 7605-1630
MD, PhD, Professor
Russian Federation, 10, Studencheskaya street, Voronezh, 394036Veronika I. Shevcova
Voronezh State Medical University
Email: shevvi17@yandex.ru
ORCID iD: 0000-0002-1707-436X
SPIN-code: 1393-7808
MD, PhD
Russian Federation, 10, Studencheskaya street, Voronezh, 394036Artem N. Shevcov
Voronezh State Medical University
Email: shan-87@yandex.ru
ORCID iD: 0000-0001-8641-2847
SPIN-code: 5647-9491
MD, PhD
Russian Federation, 10, Studencheskaya street, Voronezh, 394036Anastasia S. Kurguzova
Voronezh State Medical University
Author for correspondence.
Email: askurguzova@vrngmu.ru
ORCID iD: 0000-0003-0764-707X
SPIN-code: 1254-3033
Russian Federation, 10, Studencheskaya street, Voronezh, 394036
References
- Григорьева И.И., Раскина Т.А., Летаева М.В., и др. Саркопения: особенности патогенеза и диагностики // Фундаментальная и клиническая медицина. 2019. Т. 4, № 4. С. 105–116. [Grigorieva II, Raskina TA, Letaeva MV, et al. Sarcopenia: features of pathogenesis and diagnosis. Fundamental and clinical medicine. 2019;4(4):105–116. (In Russ).] doi: 10.23946/2500-0764-2019-4-4-105-116
- Плещёв И.Е., Ачкасов Е.Е., Николенко В.Н., Шкребко А.Н. Саркопения: современные подходы к диагностике и реабилитации // Современные проблемы науки и образования (сетевое издание). 2022. № 1. [Pleshchev IE, Achkasov EE, Nikolenko VN, Shkrebko AN. Sarcopenia: modern approaches to diagnosis and rehabilitation. Modern problems of science and education. 2022;(1). (In Russ).] Режим доступа: https://science-education.ru/ru/article/view?id=31443. Дата обращения: 27.08.2022.
- Онучина Ю.С., Гурьева И.В. Взаимосвязь саркопении и сахарного диабета типа 2 // Эндокринология: новости, мнения, обучение. 2018. Т. 7, № 4. С. 32–41. [Onuchina YuS, Guryeva IV. Interrelation of sarcopenia and type 2 diabetes mellitus. Endocrinology: news, opinions, training. 2018;7(4): 32–41. (In Russ).]
- Мокрышева Н.Г., Крупинова Ю.А., Володичева В.Л., и др. Саркопения глазами эндокринолога // Ожирение и метаболизм. 2018. Т. 15, № 3. С. 21–27. [Mokrysheva NG, Krupinova YuA, Volodicheva VL, et al. Sarcopenia through the eyes of an endocrinologist. Obesity and metabolism. 2018; 15(3):21–27. (In Russ).]
- Landi F, Cruz-Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing. 2013;42(2):203–209. doi: 10.1093/ageing/afs194
- Maliszewska K, Adamska-Patruno E, Krętowski A. The interplay between muscle mass decline, obesity, and type 2 diabetes. Pol Arch Intern Med. 2019;129(11):809–816. doi: 10.20452/pamw.15025
- Shafiee G, Keshtkar A, Soltani A, et al. Prevalence of sarcopenia in the world: A systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16:21. doi: 10.1186/s40200-017-0302-x
- Wang M, Tan Y, Shi Y, et al. Diabetes and sarcopenic obesity: Pathogenesis, diagnosis, and treatments. Front Endocrinol (Lausanne). 2020;11:568. doi: 10.3389/fendo.2020.00568
- Mu ZJ, Fu JL, Sun LN, et al. Associations between homocysteine, inflammatory cytokines and sarcopenia in Chinese older adults with type 2 diabetes. BMC Geriatr. 2021;21(1):692. doi: 10.1186/s12877-021-02622-y
- Драпкина О.М., Будневский А.В., Овсянников Е.С., и др. Саркопеническое ожирение: закономерности и парадоксы // Профилактическая медицина. 2021. Т. 24, № 1. С. 73–78. [Drapkina OM, Budnevsky AV, Ovsyannikov ES, et al. Sarcopenic obesity: patterns and paradoxes. Preventive medicine. 2021; 24(1):73–78. (In Russ).] doi: 10.17116/profmed20212401173
- Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: The health, aging, and body composition study. Diabetes. 2006;55(6):1813–1818. doi: 10.2337/db05-1183
- Мисникова И.В., Ковалева Ю.А., Климина Н.А. Саркопеническое ожирение // Русский медицинский журнал. 2017. Т. 25, № 1. С. 24–29. [Misnikova IV, Kovaleva YA, Klimina NA. Sarcopenic obesity. Russ Med J. 2017;25(1):24–29. (In Russ).]
- Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: Findings from the National Health and Nutrition Examination Survey III. PLoS One. 2010;5(5):e10805. doi: 10.1371/journal.pone.0010805
- Low S, Goh KS, Ng TP, et al. The prevalence of sarcopenic obesity and its association with cognitive performance in type 2 diabetes in Singapore. Clin Nutr. 2020;39(7):2274–2281. doi: 10.1016/j.clnu.2019.10.019
- Ali AM, Kunugi H. Screening for Sarcopenia (Physical Frailty) in the COVID-Era. Int J Endocrinol. 2021;2021:5563960. doi: 10.1155/2021/5563960
- Веселова Д.К., Белопасов В.В. Старческая астения и старческая апатия в повседневной клинической практике в условиях пандемии новой коронавирусной инфекции COVID-19 // Клиническая практика. 2022. Т. 13, № 1. C. 66–78. [Veselova DK, Belopasov VV. Senile asthenia and senile apathy in everyday clinical practice in the conditions of a pandemic of a new coronavirus infection COVID-19. Clinical practice. 2022;13(1):66–78. (In Russ).] doi: 10.17816/clinpract104831
- Atkins J, Wannamathee S. Sarcopenic obesity in ageing: Cardiovascular outcomes and mortality. Br J Nutrition. 2020; 124(10):1102–1113. doi: 10.1017/S0007114520002172
- Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci. 2020;21(2):494. doi: 10.3390/ijms21020494
- Xia MF, Chen LY, Wu L, et al. Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study. Clin Nutr. 2021;40(2): 571–580. doi: 10.1016/j.clnu.2020.06.003
- Wang H, Hai S, Liu YX, et al. Associations between sarcopenic obesity and cognitive impairment in elderly chinese community-dwelling individuals. J Nutr Health Aging. 2019;23(1):14–20. doi: 10.1007/s12603-018-1088-3
- Lim G, Lee H, Lim Y. Potential effects of resistant exercise on cognitive and muscle functions mediated by myokines in sarcopenic obese mice. Biomedicines. 2022;10(10):2529. doi: 10.3390/biomedicines10102529
- Batsis JA, Haudenschild C, Roth RM, et al. Incident impaired cognitive function in sarcopenic obesity: Data from the national health and aging trends survey. J Am Med Dir Assoc. 2021;22(4):865–872.e5. doi: 10.1016/j.jamda.2020.09.008
- Тополянская С.В. Саркопения, ожирение, остеопороз и старость // Сеченовский вестник. 2020. Т. 11, № 4. С. 23–35. [Topolyanskaya SV. Sarcopenia, obesity, osteoporosis and old age. Sechenovsky Bulletin. 2020;11(4):23–35. (In Russ).] doi: 10.47093/2218-7332.2020.11.4.23-35
- Rinonapoli G, Pace V, Ruggiero C, et al. Obesity and bone: a complex relationship. Int J Mol Sci. 2021;22(24):13662. doi: 10.3390/ijms222413662
- Lin YH, Teng MM. Association of possible sarcopenic obesity with osteoporosis and fragility fractures in postmenopausal women. Arch Osteoporos. 2022;17(1):65. doi: 10.1007/s11657-022-01107-8
- Hernández-Martínez P, Olmos JM, Llorca J, et al. Sarcopenic osteoporosis, sarcopenic obesity, and sarcopenic osteoporotic obesity in the Camargo cohort (Cantabria, Spain). Arch Osteoporos. 2022;17(1):105. doi: 10.1007/s11657-022-01146-1
- Hsu KJ, Liao CD, Tsai MW, et al. Effects of exercise and nutritional intervention on body composition, metabolic health, and physical performance in adults with sarcopenic obesity: A meta-analysis. Nutrients. 2019;11(9):2163. doi: 10.3390/nu11092163